Curavit

What Curavit does

Curavit Clinical Research is a Boston-based virtual contract research organization (VCRO) that designs and executes decentralized clinical trials (DCTs) for pharmaceutical sponsors, digital therapeutics companies, medical device manufacturers, and academic research institutions. Founded in 2020 by Joel Morse and Dave Hanaman — both previously co-founders of C3i Healthcare Connections — the company positions itself as an 'Innovation CRO' with exclusive focus on virtual and decentralized trial methodologies, and reports approximately 400 decentralized trials deployed across 70 countries serving more than one million participants.

The company's core offering is its Virtual Clinical Site (VCS) platform, which serves as a centralized hub for trial activities and clinical data in decentralized and hybrid trials, integrating best-in-class third-party tools for recruitment, screening, consent, and monitoring. Curavit complements this platform with a full suite of CRO services spanning study design, FDA submissions, patient recruitment, data management, and regulatory compliance, plus an add-on Health Economics and Outcomes Research (HEOR) service that captures real-world data to support market access and payer coverage. Services are delivered through a flexible Functional Service Provider (FSP) model that can be deployed end-to-end or unbundled to integrate with sponsor teams.

Curavit operates on a project-based professional services revenue model with custom enterprise pricing per trial scope, duration, and complexity. The company markets through direct enterprise sales, thought leadership content, industry conferences (DIA, SCOPE, LSI, CGT Summit), and association memberships (DTRA, ATA, DIA, BioUtah). The company has raised $5 million in Series A funding from Osage Venture Partners in November 2022 and has been recognized with PM360 Innovators Awards in 2021 and 2023. Named customers are predominantly early-stage digital therapeutics startups, with case-study claims of 200% faster enrollment and 50% cost reductions compared to traditional site-centric models.

Name

Curavit

Legal name

Curavit Clinical Research

Website

https://curavit.io

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Curavit Clinical Research is a Boston-based virtual contract research organization that designs and executes decentralized clinical trials for pharmaceutical sponsors, digital therapeutics companies, and medical device manufacturers through its Virtual Clinical Site platform and flexible CRO service model.

Ownership category

akta.pro rank

Product category

Decentralized Clinical Trial Services

NAICS

Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Management Consulting Services (8742)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industry

Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI)

Keywords

• Decentralized clinical trials
• Virtual contract research
• Clinical trial services
• Digital therapeutics trials
• Remote clinical site

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. CRO Services: Curavit operates as a virtual contract research organization (VCRO) offering comprehensive CRO services for sponsors conducting clinical trials. Services are offered as a flexible Functional Service Provider (FSP), providing comprehensive support that can be deployed end-to-end or unbundled to integrate with sponsors' internal teams and other partners. Revenue is generated through project-based contracts for trial design, execution, recruitment, monitoring, and data management services.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

Curavit operates as a virtual contract research organization (VCRO) that designs and executes decentralized and hybrid clinical trials for pharmaceutical sponsors, digital therapeutics companies, medical device manufacturers, and academic research institutions. Its core offering is the Virtual Clinical Site (VCS) platform combined with comprehensive CRO services spanning study design, recruitment, regulatory submissions, and HEOR evidence generation, with particular specialization in digital therapeutics clinical development.

Product overview

Curavit operates as an Innovation CRO (Virtual Contract Research Organization) offering a unified portfolio of decentralized clinical trial services. The core offerings include the Virtual Clinical Site (VCS) platform for remote trial execution and comprehensive CRO Services spanning study design through FDA submission. The company provides HEOR Services as an add-on capability to generate health economics evidence, all delivered through a flexible Functional Service Provider (FSP) model that can be deployed end-to-end or unbundled to integrate with sponsors' internal teams. The VCS platform integrates best-in-class digital tools to support scalable, efficient clinical research across decentralized and hybrid trial designs.

Differentiator

Problem solved

Functional benefit

Products and services

• Virtual Clinical Site (VCS) Platform Virtual Clinical Site platform designed to support CROs, academic research institutions, and sponsors to run trials with decentralized elements, enabling nationwide participant recruitment, virtual visits, remote data collection, and integration of best-in-class digital tools for scalable clinical research.
• CRO Services Comprehensive CRO services for sponsors covering study design, FDA submissions, patient-centric trial execution, recruitment, data quality management, and regulatory compliance, purpose-built for decentralized and hybrid clinical trials.
• Health Economics and Outcomes Research (HEOR) Services Standalone services to capture real-world data demonstrating health economic impact and therapeutic value of digital health interventions, supporting market access, payer coverage, and reimbursement decisions for digital therapeutics and medical device sponsors.

Quantifiable outcome

• 200% faster enrollment compared to traditional trial models
• +4 more outcomes

Named customers7 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered core and supporting.

• CenmedcoreStrategic or Co-development Partner · 14 November 2025Strategic collaboration to improve clinical trial kitting and logistics for decentralized trials. The partnership aims to enhance efficiency, reduce trial start-up times, and support the growing demand for hybrid and decentralized trial models through integrated customized services and nationwide distribution.
• 1nHealthsupportingTechnology or IntegrationDigital first recruiting partnership for decentralized clinical trials, enabling enhanced patient identification and recruitment capabilities.
• ixlayersupportingTechnology or IntegrationTechnology partnership for laboratory testing and diagnostics integration in decentralized clinical trials.
• Milliman ContxtsupportingTechnology or IntegrationPartnership to bring claims-based medical history into the clinical trial qualification process earlier, reducing screen-fail rates and improving recruitment efficiency.
• American Telemedicine AssociationsupportingOthersIndustry association partnership supporting the advancement of digital health and decentralized clinical trials. Andy Molnar, SVP and Head of Digital Health at ATA, serves as a partner advocate for DTx adoption.
• Decentralized Trials & Research Alliance (DTRA)supportingOthersIndustry consortium working to advance decentralized clinical trial adoption and standards.
• DIAsupportingOthersMember organization supporting innovation in clinical research and regulatory science.

Scale indicators7 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Parexel: Parexel is a large incumbent CRO offering decentralized clinical trial services as part of its full-service portfolio. It targets similar pharma and biotech sponsors but competes on scale and breadth rather than DCT specialization.
• ICON plc: ICON is a top-3 global CRO offering decentralized and hybrid trial solutions to pharma and biotech sponsors. It overlaps with Curavit on DCT execution but competes primarily as a broad, full-service CRO rather than a DCT specialist.
• Fortrea (formerly Labcorp Drug Development): Fortrea is a global CRO with established DCT capabilities formed from the spin-out of Labcorp's clinical development business. It competes with Curavit on decentralized trial execution but as part of a much broader clinical and lab services portfolio.
• IQVIA: IQVIA is the world's largest CRO with a growing portfolio of decentralized and hybrid trial capabilities. It competes with Curavit for large pharma DCT engagements but operates at vastly greater scale and as part of a much broader services portfolio.

Direct peers

• Science 37: Science 37 is a DCT-focused virtual CRO operating a 'Metasite' model that closely parallels Curavit's Virtual Clinical Site approach. Both companies target decentralized trial execution for pharma and biotech sponsors with technology-enabled patient recruitment and remote monitoring.
• ObvioHealth: ObvioHealth is a virtual CRO running fully decentralized and hybrid clinical trials using its own platform, directly comparable to Curavit's VCRO positioning. Both companies target sponsors seeking DCT execution with proprietary technology.
• Medable: Medable provides a decentralized clinical trial platform used by sponsors and CROs, directly overlapping with Curavit's VCS platform. Both companies pursue DCT execution with emphasis on eConsent, remote data capture, and patient-centric trial design for pharma and digital therapeutics sponsors.
• THREAD Research: THREAD provides a decentralized clinical trial platform supporting eCOA, ePRO, telehealth visits, and remote patient engagement — directly comparable to Curavit's VCS feature set. Both serve as DCT execution partners for sponsors and CROs.

Emerging players

• Castor: Castor offers an eClinical platform supporting decentralized trial design with eCRF, eConsent, and remote data capture — partially overlapping with Curavit's VCS. Castor is primarily a technology platform rather than a full-service CRO, making it a partial competitor on the platform layer.
• Clinical Ink: Clinical Ink provides eCOA, ePRO, and direct data capture technology used in decentralized and hybrid clinical trials, comparable to specific VCS platform features. It is a technology vendor rather than a full-service CRO, positioning it as a partner and partial competitor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/curavitclinical
• LinkedInlinkedin.com/company/curavit

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Curavit